Entera Bio Ltd. Book value per Share

Book value per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending September 29, 2019 was 0.33 (a -38.89% decrease compared to previous quarter)
  • Year-over-year quarterly Book value per Share decreased by -62.37%
  • Annual Book value per Share for 2018 was 0.88 (a -112.56% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of Entera Bio Ltd.

Most recent Book value per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Book value per Share of Entera Bio Ltd.

Entera Bio Ltd. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.33 0.54 0.67
2018 0.88 0.0 0.0 0.0 0.88
2017 0.0 -7.03

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.